Anti-Tau therapies for Alzheimer's disease

M. Fadus, J. Harrison, Venkata Kolli

Research output: Contribution to journalReview article

Abstract

The prevalence of Alzheimer's disease (AD) is increasing and is estimated to reach 115 million worldwide by 2050. However, the current pharmacological armamentarium of AD treatments is limited to cholinesterase inhibitors and memantine. Anti-amyloid therapies had been a focus of drug development in AD, but none of the agents were able to demonstrate clinical utility in treating AD. Advances in neurobiology have implicated tau hyperphosphorylation in the etiopathogen esis of AD. In this article, we discuss the role of tau pathology in AD and potential pharmacological targets that include inhibition of tau aggregation, microtubule stabilization, tau immunotherapy, tau phosphorylation and O-GlcNAcylation and increasing tau degradation and clearance.

Original languageEnglish (US)
Pages (from-to)485-495
Number of pages11
JournalDrugs of the Future
Volume41
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Alzheimer Disease
Therapeutics
Pharmacology
Memantine
Neurobiology
Cholinesterase Inhibitors
Amyloid
Microtubules
Immunotherapy
Phosphorylation
Pathology
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Anti-Tau therapies for Alzheimer's disease. / Fadus, M.; Harrison, J.; Kolli, Venkata.

In: Drugs of the Future, Vol. 41, No. 8, 01.08.2016, p. 485-495.

Research output: Contribution to journalReview article

Fadus, M. ; Harrison, J. ; Kolli, Venkata. / Anti-Tau therapies for Alzheimer's disease. In: Drugs of the Future. 2016 ; Vol. 41, No. 8. pp. 485-495.
@article{9aa3d938b04740fbb8c5341486164d3f,
title = "Anti-Tau therapies for Alzheimer's disease",
abstract = "The prevalence of Alzheimer's disease (AD) is increasing and is estimated to reach 115 million worldwide by 2050. However, the current pharmacological armamentarium of AD treatments is limited to cholinesterase inhibitors and memantine. Anti-amyloid therapies had been a focus of drug development in AD, but none of the agents were able to demonstrate clinical utility in treating AD. Advances in neurobiology have implicated tau hyperphosphorylation in the etiopathogen esis of AD. In this article, we discuss the role of tau pathology in AD and potential pharmacological targets that include inhibition of tau aggregation, microtubule stabilization, tau immunotherapy, tau phosphorylation and O-GlcNAcylation and increasing tau degradation and clearance.",
author = "M. Fadus and J. Harrison and Venkata Kolli",
year = "2016",
month = "8",
day = "1",
doi = "10.1358/dof.2016.041.08.2491615",
language = "English (US)",
volume = "41",
pages = "485--495",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - Anti-Tau therapies for Alzheimer's disease

AU - Fadus, M.

AU - Harrison, J.

AU - Kolli, Venkata

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The prevalence of Alzheimer's disease (AD) is increasing and is estimated to reach 115 million worldwide by 2050. However, the current pharmacological armamentarium of AD treatments is limited to cholinesterase inhibitors and memantine. Anti-amyloid therapies had been a focus of drug development in AD, but none of the agents were able to demonstrate clinical utility in treating AD. Advances in neurobiology have implicated tau hyperphosphorylation in the etiopathogen esis of AD. In this article, we discuss the role of tau pathology in AD and potential pharmacological targets that include inhibition of tau aggregation, microtubule stabilization, tau immunotherapy, tau phosphorylation and O-GlcNAcylation and increasing tau degradation and clearance.

AB - The prevalence of Alzheimer's disease (AD) is increasing and is estimated to reach 115 million worldwide by 2050. However, the current pharmacological armamentarium of AD treatments is limited to cholinesterase inhibitors and memantine. Anti-amyloid therapies had been a focus of drug development in AD, but none of the agents were able to demonstrate clinical utility in treating AD. Advances in neurobiology have implicated tau hyperphosphorylation in the etiopathogen esis of AD. In this article, we discuss the role of tau pathology in AD and potential pharmacological targets that include inhibition of tau aggregation, microtubule stabilization, tau immunotherapy, tau phosphorylation and O-GlcNAcylation and increasing tau degradation and clearance.

UR - http://www.scopus.com/inward/record.url?scp=84990238294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990238294&partnerID=8YFLogxK

U2 - 10.1358/dof.2016.041.08.2491615

DO - 10.1358/dof.2016.041.08.2491615

M3 - Review article

VL - 41

SP - 485

EP - 495

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 8

ER -